Overview

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity. How QGE031 is broken down by the body and the impact it has on different blood and tissue markers will also be explored.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals